FDA's Scott Got­tlieb is field­ing a new team of re­cruiters to start scout­ing top tal­ent

Biotech ex­ecs have been bull­ish sup­port­ers of the FDA in re­cent years, of­fer­ing their ap­pre­ci­a­tion of faster re­view times with new pro­grams like the break­through ther­a­py des­ig­na­tion. But if there’s one re­cur­rent gripe you hear fre­quent­ly, it’s that the reg­u­la­tors bio­phar­ma com­pa­nies and pa­tient ad­vo­cates deal with don’t have the right kind of sci­en­tif­ic ex­pe­ri­ence for the drugs un­der re­view — es­pe­cial­ly as you stray out­side of on­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.